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Abstract
Background: Chemokine receptor 5 (CCR5) is hypothesized to drive the lymphocyte migration to central nervous
system in flavivirus encephalitis, and the non-functional CCR5Δ32 genetic variant was identified as a risk factor of a
West Nile virus infection and of tick-borne encephalitis (TBE). We have attempted to investigate how CCR5
expression corresponds to the clinical course and severity of TBE.
Methods: We have repeatedly studied CCR5 expression in 76 patients during encephalitic and convalescent TBE
phase, analyzing its association with clinical features, cerebrospinal fluid (csf) pleocytosis, and concentrations of
CCR5 ligands (chemokines CCL3, CCL4, and CCL5) and CCR5 genotype. Fifteen patients with neuroborreliosis, 7 with
aseptic meningitis, 17 in whom meningitis/encephalitis had been excluded, and 18 healthy blood donors were
studied as controls. Expression of CCR5 was measured cytometrically in blood and csf-activated Th lymphocytes
(CD3+CD4+CD45RO+). Concentrations of chemokines in serum and csf were measured immunoenzymatically, and
CCR5Δ32 was detected with sequence-specific primers. Data were analyzed with non-parametric tests, and p < 0.05
was considered significant.
Results: The blood expression of CCR5 did neither differ between the groups nor change in the course of TBE. The
CCR5 expression in the inflammatory csf was several-fold increased in comparison with blood but lower in TBE than
in neuroborreliosis. The csf concentration of CCL5 was increased in TBE, the highest in the most severe presentation
(meningoencephalomyelitis) and correlated with pleocytosis. The CCR5Δ32/wt genotype present in 7 TBE patients
was associated with a decreased CCR5 expression, but enrichment of csf Th population in CCR5-positive cells and
the intrathecal inflammatory response were preserved, without a compensatory increase of CCL5 expression.
Conclusions: We infer CCR5 and CCL5 participate in the response to TBE virus, as well as to other neurotropic
pathogens. The intrathecal response to TBE is not hampered in the bearers of a single copy of CCR5Δ32 allele,
suggesting that the association of CCR5Δ32 with TBE may be mediated in the periphery at the earlier stage of the
infection. Otherwise, a variability of the CCR5 expression in the peripheral blood lymphocytes seems not to be
associated with a variable susceptibility to TBE.
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Background
Tick-borne encephalitis (TBE) is caused by a tick-borne
encephalitis virus (TBEV) of Flavivirus genus (family
Flaviviridae), transmitted by Ixodes ticks. It is endemic
in the temperate zone of Asia and Eastern and Central
Europe, where several thousand cases are reported annu-
ally, including over 200 cases in Poland [1–3]. Infection
with the European TBEV type is often asymptomatic or
results in a mild, flu-like disease. The second phase of
the infection, characterized by central nervous system
(cns) involvement, occurs in a minority of cases and pre-
sents an uncomplicated meningitis, meningoencephalitis
of highly variable severity or meningoencephalomyelitis
[4–8]. This wide range of clinical presentations suggests
that host factors contribute to the susceptibility to the
disease and to its severity. The outcome of the infection
may be decided at several points, including the local
virus replication and spread from the tick-bite site, the
peripheral response immune/inflammatory, the pene-
tration of the blood-brain barrier, and finally, the type
and extent of the response within cns [9]. Nervous
tissue pathology in TBE is complex and involves both
the direct cytopathic effect of TBEV on the infected
neural cells and the secondary immune-mediated
damage [9–13].
The cerebrospinal fluid (csf) pleocytosis is a hallmark
of the intrathecal inflammatory response during cns in-
fection. In TBE, the lymphoid pleocytosis is relatively
low and dominated by Th CD4+ lymphocytes, mostly of
Th1 subset, with addition of T CD8+ cells [14–16]. The
role played by different cell populations, including T
CD4+ and T CD8+ lymphocytes, is debatable [17]. Both
animal experiments and autopsy studies in fatal human
TBE cases suggest Th CD4+ lymphocytes are indispens-
able for the TBEV control and elimination while Tc CD8
+ cells contribute to cns immunopathology [13, 18].
Leukocyte migration into cns is driven by cytokines of
the chemokine family, and a pattern and timing of ex-
pression of particular chemokines and their receptors
determines the composition of the infiltrate [19, 20].
Chemokine receptor 5 (CCR5) is a receptor for chemo-
kine ligand 3 (CCL3, previously named MIP-1α), CCL4
(MIP-1β), and CCL5 (RANTES) expressed on memory
type and activated Th1 CD4+ lymphocytes, T CD8+
lymphocytes, and monocytes, and involved in Th1-
type inflammatory/immune response [21–25]. Its
expression is not increased directly on lymphocyte ac-
tivation but is up-regulated by pro-inflammatory and
Th1-related cytokines (interleukin 2—IL-2, IL-12,
tumor necrosis factor alpha—TNF-α, interferon
gamma—IFN-γ) and may be decreased in anti-
inflammatory/Th2 environment [21, 24, 25]. Several
studies show increased CCR5 expression by lympho-
cytes in the inflammatory csf [26–30], but the data
on its role in flavivirus encephalitis are mostly
indirect.
The CCR5Δ32 deletion in CCR5 gene results in a syn-
thesis of a truncated protein and the lack of functional
CCR5 in homozygotes [24, 31]. In CCR5Δ32 heterozy-
gotes, both the constitutive expression of CCR5 and its
induction by pro-inflammatory stimuli are significantly
reduced [24, 25]. The lack of CCR5 confers no evident
pathology, probably due to a redundancy within the che-
mokine ligand/receptor network, but it hampers protect-
ive responses against certain viral and parasitic
pathogens in animal models [31–34]. In humans, im-
paired CCR5 function has been suggested as a risk factor
of flavivirus infections. A case of a severe viscerotropic
disease after vaccination with an attenuated yellow fever
vaccine has been described in a patient heterozygous for
both CCR5Δ32 and a mutation in a promoter region of
the CCL5 gene [35]. CCR5Δ32 homozygocity has been
linked to the increased susceptibility to West Nile virus
(WNV), which is a neurotropic flavivirus related to
TBEV and responsible for a similarly wide spectrum of
clinical presentations, from asymptomatic through mild
febrile disease to severe encephalitis [36, 37]. Epidemio-
logic studies have shown an increased risk of the clinic-
ally overt disease in CCR5Δ32 homozygotes infected
with WNV, which has been hypothesized to result from
the impaired lymphocyte influx into csf [38–40]. This
findings prompted studies on CCR5Δ32 distribution in
TBE patients, which have shown the increased risk of
TBEV meningitis/meningoencephalitis in CCR5Δ32
bearers [41, 42]. However, the majority of patients with
TBE are the wild type allele homozygotes, pointing to a
role of additional host factors in defining the susceptibil-
ity to TBEV. These factors, for example, individually
variable expression of inflammatory and immunoregula-
tory cytokines, might act either independently of CCR5
pathway or by influencing the CCR5 expression. The lat-
ter is highly variable in peripheral blood T lymphocytes
in CCR5 wt/wt homozygotes and probably determined
in a multi-factorial way [25]. One of the proposed mech-
anisms influencing an individual level of CCR5 expres-
sion is its down-regulation by its ligands, described in
vitro for CCL5 [43] and as a correlation in vivo for
CCL3 [44].
To clarify the role of CCR5 expression and CCR5
genotype in TBE, we have attempted to evaluate (1) if
CCR5 expression in the activated Th lymphocyte popu-
lation is altered in TBE and/or associated with its clin-
ical presentation, (2) if there is a difference in the
baseline expression of CCR5 in TBE patients and the
general population, (3) how CCR5 expression in TBE is
related to the concentrations of its ligand chemokines,
and (4) how the CCR5 and its ligands expression in TBE
associate with the CCR5Δ32 allele.
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Methods
Patients
The patients hospitalized in the Department of Infec-
tious Diseases and Neuroinfections of the Medical
University in Białystok with the serologically confirmed
TBEV infection were enrolled into the study and evalu-
ated on admission (examination I), in the early convales-
cent period prior to discharge 12–16 days later
(examination II) and during control visit 5–6 weeks after
the admission (examination III). The blood and csf sam-
ples for the purpose of the study were obtained together
with the material drawn for the diagnostic purposes at
these time points, if and when indicated clinically, be-
cause of that, not all the samples were available from all
the patients.
Anti-TBEV IgM antibodies were detected with
Enzygnost Anti-TBE/FSME IgM kit from Siemens
(Munich, Germany), following the standard procedure.
All the patients included in the study group were ei-
ther IgM-seropositive on admission or seroconverted
by the time of the discharge from hospital.
The group consisted of 76 patients: 6 with meningoen-
cephalomyelitis, 33 with meningoencephalitis, 34 with
uncomplicated meningitis, and 3 with a flu-like infec-
tion. Of patients with meningoencephalitis or menin-
goencephalomyelitis, 15 had mild presentation with
isolated minor neurologic abnormalities (paresthesia,
tremor, pathologic reflexes) and 24 had moderate to se-
vere presentation with altered mental status, paresis
and/or multiple focal neurologic symptoms. Of these,
blood samples were available for CCR5 cytometric study
from 36 patients in examination I, 42 in examination II,
and 25 in examination III, and csf samples from 25, 16,
and 6 patients, respectively.
Additionally, blood samples from 3 patients hospital-
ized because of the acute febrile infection, who devel-
oped TBEV encephalitis within following 2 weeks, were
studied for CCR5 expression and retrospectively classi-
fied as obtained during the first (peripheral) phase of
TBE (before the examination I time point), but they
were not included in the main study group and statis-
tical analysis.
The control blood samples were obtained from (1)
healthy blood donors (n = 18); (2) patients hospitalized
because of acute febrile infections, without meningitis
(n = 7); and (3) patients hospitalized because of a
headache of non-infectious etiology (n = 9). To put csf
findings in context, CCR5 expression was studied in a
group of patients with meningitis of non-TBEV eti-
ology at analogous time-points as in TBE patients: 15
patients with early neuroborreliosis (paired csf avail-
able from 7 in examination I, 4 in II, and 6 in III)
and 7 patients with non-TBEV aseptic meningitis (in-
cluding csf samples from 3 in examination I and
follow-up examination II and III samples in one of
them).
The pilot analysis of lymphocyte fractions was per-
formed in a subset of TBE samples, including blood ob-
tained on admission from 31 patients and csf from 9
patients (6 with meningitis and 3 with severe meningo-
encephalitis, 5 of them re-evaluated at examination II
and 4 at examination III), as well as in a blood of a ma-
jority of hospitalized control subjects.
Genotyping was performed in 47 of TBE patients in
whom any CCR5 cytometric data were available and in
15 of the healthy controls, as a part of a larger genotyp-
ing study conducted simultaneously in our center.
The concentrations of CCL3, CCL4, and CCL5 were
measured in serum and csf of a pilot subgroup of pa-
tients studied cytometrically: 11 with TBE, 4 with neuro-
borreliosis, 4 with other lymphocytic meningitis, and 5
in controls without active infection. Following that, add-
itional 45 patients were studied for CCL5 concentration
in csf on admission and before discharge (in this group,
we have included five additional TBE patients with
CCR5Δ32/wt genotype not originally enrolled in the cy-
tometric study). Of the total group of 56 TBEV-infected
patients in whom CCL5 csf concentration was studied, 1
had flu-like infection, 22 meningitis, 29 meningoenceph-
alitis (13 mild and 16 moderate to severe), and 4 menin-
goencephalomyelitis. Forty-two of them were genotyped,
32 were wt/wt homozygotes and 10 CCR5Δ32/wt
heterozygotes.
The participants gave informed consent for entry into
the study, which was approved by the Ethics Committee
of the Medical University in Białystok (approval number
R-I-002/372/2011).
Laboratory examinations
Basic inflammatory parameters intrathecally (total
leukocyte and lymphocyte csf count, csf total protein
and albumin concentration) and in the periphery
(leukocytosis, lymphocytosis) were measured with stand-
ard laboratory techniques.
The 1 ml samples of the material for flow cytometry
were collected into EDTA-coated tubes (blood) and sterile
plastic tubes (csf) and analyzed within 6 h on FACSCali-
bur cytometer. Each time, 20 μl of each monoclonal anti-
body solution was added to 100 μl of whole blood and
incubated for 30 min at room temperature in dark. The
blood samples were then treated with lysing solution to
lyse erythrocytes and both blood and csf samples were
washed with PBS directly before flow cytometry. Simult-
est™ IMK-Lymphocyte kit from BD Biosciences (San Jose,
California, USA) was used to study peripheral blood and
csf lymphocyte fractions, strictly following the manufac-
turer’s instructions. The test is based on a flow cytometry
principle and uses pairs of murine monoclonal antibodies
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(one conjugated with FITC and the other with PE) to
measure the fraction of total T lymphocytes (CD3+), T
helper/inducer lymphocytes (CD3+CD4+), T suppressor/
cytotoxic lymphocytes (CD3+CD8+), B lymphocytes
(CD19+), and natural killer (NK) lymphocytes (CD3-
CD16 and/or CD56+). The read-outs were analyzed with
Simultest IMK-Lymphocyte software. The results in a rep-
resentative blood and csf paired samples are presented in
Fig. 1.
For CCR5 evaluation, the mouse anti-human mono-
clonal antibodies: PE-labeled anti-CD3 IgG2aκ (clone
HIT3a), APC-labeled anti-CD4 IgG1κ (clone RPA-T4),
Fig. 1 The lymphocyte populations in blood and cerebrospinal fluid of a TBE patient. The representative paired peripheral blood (PBMC—rows 1
and 3 from top) and csf (rows 2 and 4) samples collected from a TBEV-infected patient on admission to hospital were analyzed with Simultest
IMK-Lymphocyte, as described in “Methods.” From the left to right in the upper two rows: the gated lymphocyte population; the negative control;
identification of B (CD19+) and T (CD3+) lymphocytes; in the lower two rows: T CD3 + CD4+ lymphocytes; T CD3+CD8+ lymphocytes; and NK
cells (CD3-CD16+CD56+). The csf lymphocyte population is enriched in CD3+CD4+ cells in comparison with the peripheral blood, at the expense
of the other lymphocyte fractions, especially B lymphocytes
Grygorczuk et al. Journal of Neuroinflammation  (2016) 13:45 Page 4 of 17
PE-Cy™5 anti-CD45RO IgG2aκ (clone UCHL1), and
FITC-labeled anti-CD195 (CCR5) IgG2aκ (clone 2D7/
CCR5) were used. PE-Cy™5-conjugated mouse IgG2aκ
isotype control was used to assure correct gating of
CD45RO+ cells, and the cutoff level for CCR5 expres-
sion was determined with FITC-stained mouse IgG2aκ
isotype control. Eventually, CCR5 expression was mea-
sured in the gated population of CD3+CD4+CD45RO+
cells and expressed as a mean fluorescence index (MFI),
calculated from the fraction of CCR5-positive cells and
geometric mean of CCR5 fluorescence in CCR5+ popula-
tion. Data acquisition was performed with CellQuest soft-
ware (Becton Dickinson). The detailed gating strategy and
results in a representative patient are shown in Fig. 2.
QIAamp DNA Blood Mini Kit (QIAgen, Hilden,
Germany) was used to extract genomic DNA from the
blood samples collected to EDTA tubes, following the
manufacturer’s protocol. DNA was re-suspended in
200 μL of AE buffer (QIAgen, Hilden, Germany) and
stored at 4 °C for further analyses. To analyze CCR5Δ32
variation, PCR with sequence-specific primers was used
as described previously [45]. Visualization under UV
light was performed after electrophoresis on the 2.5 %
agarose gel (SIGMA, Saint Louis, USA) stained with
DNA-star dye (Lonza Inc., Rockland, USA).
Chemokine concentrations were measured in serum
samples obtained from 5 ml of blood collected for clot-
ting and centrifuged within an hour after collection and
in csf samples obtained on the same day. All the mate-
rials were frozen on the day of collection, kept at −70 °C
and thawed directly before performing examinations.
CCL3, CCL4, and CCL5 concentrations were measured
with commercial ELISA kits from R&D Systems, Inc.
(Minneapolis, MN, USA), strictly following the manufac-
turer’s instructions. The minimum detectable concentra-
tions were 10.0 pg/ml for CCL3, 4.0 pg/ml for CCL4,
Fig. 2 CCR5 expression in blood and cerebrospinal fluid Th lymphocytes from a TBE patient. The representative FACS plots demonstrating the
gating strategy and the measured CCR5 (CD195) expression in CD3+CD4+CD45RO+ lymphocyte population in blood (peripheral blood
mononuclear cells—PBMC, upper panel) and in cerebrospinal fluid (csf, lower panel) obtained on admission to hospital from a TBEV-infected
patient. Left: T lymphocytes were gated based on CD3 and side scatter dot plot (gate R1). Middle: CD4+CD45RO+ T lymphocytes were gated in
selected R1 population based on CD4 and CD45RO dot plot (gate R3). Isotype controls from the same blood and csf samples were used to define
the CD45RO+ population. Gate R2 contains CD4+CD45-negative T lymphocytes. Right: a histogram of CD195 expression intensity (dark gray)
measured on gate R3 (light gray—isotype control). The tendency for a preferential migration of T lymphocytes to csf (left), for the enrichment of
the T lymphocyte population that has migrated into csf in CD4+CD45RO+ lymphocytes (center) and for the increased CCR5 expression in the csf
CD4+CD45RO+ cells (right) is visible
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and 2.0 pg/ml for CCL5; read-out below the detection
limit were considered zero.
Statistical analysis
The statistical analysis was performed with STATISTICA
10 software with non-parametric tests: Kruskal-Wallis
ANOVA and Mann-Whitney U test for independent,
Friedmann ANOVA and Wilcoxon pair tests for
dependent variables. CCR5 expression and chemokine
concentrations were compared between the study groups
and analyzed with the respect to the clinical manifestation
(meningitis, meningoencephalitis, memingoencephalo-
myelitis), severity (mild versus moderate/severe cns in-
volvement, presence versus lack of altered consciousness),
clinical course (typical biphasic with a distinct flu-like
phase of peripheral infection versus monophasic), and
CCR5Δ32 genotype in TBE group. Correlation between
CCR5 expression and CCL5 concentration, as well as be-
tween these variables and basic laboratory parameters,




On admission, TBE patients had higher median
leukocytosis (9.250/μl) and lower lymphocyte count
(1.295/μl) than other study group, which normalized to
6.875/μl and 2.076/μl, respectively, in examination II be-
fore discharge. The TBE peripheral blood lymphocyte
population contained 68 % of T CD3+ cells (890/μl), in-
cluding 33 % of CD4+ (519/μl) and 24 % of CD8+ lym-
phocytes (334/μl) and 16 % of B cells (225/μl) and 13 %
of NK cells (178/μl) on admission. Both the proportion
and absolute number of CD3+ and CD3+CD4+ tended
to be lower in TBE than in other study groups but in-
creased to 74 % (1289/μl) and 43 % (889/μl),
respectively, before discharge, undistinguishable from
the other subjects.
Of the gated CD3+CD4+ lymphocytes, a median of
42 % was of an activated/memory subtype, which was
stable in examinations I, II, and III and did not differ
from other study groups. The CCR5 expression did not
differ between the TBE patients and other groups, in-
cluding healthy controls, did not differ between the sub-
groups of TBE patients, and did not change between
examinations I, II, and III, but was highly individually
variable with values in examinations I and II in the same
patients correlated (correlation strength 0.6, p < 0.05). In
three patients studied in the first phase of the disease
and three patients with flu-like TBEV infection, the
CCR5 expression fits in the range of values found in the
neurologic phase.
Cerebrospinal fluid cytometry
Basic csf inflammatory parameters in TBE, neuroborre-
liosis, and other meningitis patients are summed up in
Table 1. On admission, TBE patients had lower pleocyto-
sis and especially the lower csf lymphocyte count in
comparison with neuroborreliosis and other lymphocytic
meningitis patients. While there was a general tendency
for a simultaneous normalization of the csf inflamma-
tory parameters in all the neuroinfection groups, the
lymphocyte count in TBE was constant between exami-
nations I and II and as a result, the lymphocyte contri-
bution to pleocytosis tended to increase from slightly
over 50 % on admission to >95 % in almost all the con-
valescent samples. There was a higher pleocytosis in
TBE meningoencephalomyelitis than in other TBE
presentations and an analogous tendency for the
lymphocytosis.
The lymphocyte subpopulations in csf of nine TBE pa-
tients on admission are shown in Table 2; repeated
Table 1 The median values of the basic cerebrospinal fluid parameters in the patient groups studied cytometrically for CCR5
expression
Pleocytosis/μl Lymphocyte count/μl Protein (mg/dl)d Albumin (mg/dl)e
I II III I II III I II III I II III
TBE total (n = 76)f 73a 43c 17c 39a 42 16c 56 58 43c 41 39 29c
TBE—M (n = 34)f 79 52 18c 44 47 18c 55 59 42c 43 42 30c
TBE—ME (n = 33)f 64 41 13c 37 34 14c 57 55 42c 40 37 27c
TBE—MEM (n = 6)f 171b 38 26 77 30 23 74 86 59 52 41 39
NB (n = 15)f 234a 52c 21c 207a 50c 18c 119 60c 44c 77 46c 33c
AM (n = 7)f 213a 22c 15 102a 20c 33 60 44c 43 41 33c 22
TBE tick-borne encephalitis, M meningitis, ME meningoencephalitis, MEM meningoencephalomyelitis, NB neuroborreliosis, AM aseptic meningitis (non-TBE, non-NB)
I—examination on admission to hospital; II—10–14 days later, III—6–8 weeks later
asignificant difference between TBE and other neuroinfection groups (p < 0.05)
bsignificant difference in comparison with TBE-M and TBE-ME groups
csignificant decrease in comparison with examination I (p < 0.05)
dthe upper limit of normal is 45 mg/dl
ethe upper limit of normal is 30 mg/dl
fthe group size in examination I; in examinations II and III some patients from each group were not available for study
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examination in the same patients in the convalescent
period gave essentially the same results (not shown).
There was a higher CD8+ cell percentage in the csf from
patients with severe meningoencephalitis than with
meningitis (p < 0.05) and in patients with altered
consciousness than in those with normal mental status
(p = 0.055). Activated CD45RO+ cells constituted a me-
dian of 75 % of csf Th lymphocyte population in exam-
ination I, 56 % in examination II, and 71 % in
examination III (36 cells/μl, 21/μl ,and 11/μl, respect-
ively), independent of the clinical manifestation. In com-
parison with circulating lymphocytes, csf lymphocyte
population of the TBE patients was significantly enriched
in T CD3+ and Th CD3+CD4+ and especially in acti-
vated Th CD3+CD4+CD45RO cells at all three examin-
ation time-points (Figs. 1 and 2).
CCR5 was expressed by a median 39 % of Th CD3
+CD4+CD45RO lymphocytes in the TBE csf on admis-
sion—an over twofold and highly significant enrichment
in comparison with the peripheral blood lymphocyte
population. There was a further increase in CCR5-
positive fraction in examination II (48 %) sustained in
examination III (57 %). As a result, the absolute number
of CCR5-positive activated Th lymphocytes in csf was
relatively constant in spite of a decreasing total pleocyto-
sis: 12 cell/μl in examination I, 14/μl in examination II,
and 6/μl in examination III, when this fraction consti-
tuted almost 40 % of the total csf leukocyte population.
The intensity of staining of CCR5-positive cells tended
to be higher in csf than in peripheral blood, resulting in
several-fold increased MFI (Figs. 2 and 3). CCR5 csf ex-
pression tended to be similarly increased in a small
group of patients with aseptic meningitis, while in neu-
roborreliosis, it was even higher: 52 % of activated Th
lymphocytes was CCR5-positive, in combination with
higher csf lymphocyte count resulting in 10 times higher
absolute number of activated CCR5+ cells than in TBE.
Within TBE group, csf CCR5 expression tended to
be relatively high in patients with meningoencephalo-
myelitis, but the number of csf samples available for
cytometry was too small for a statistical confirmation.
There was no difference between meningitis and
Table 2 The lymphocyte subpopulations in the cerebrospinal fluid obtained on admission to hospital from a subset of tick-borne
encephalitis (TBE) patient group, assessed as described in “Methods.” The results are shown as a median fraction of the lymphoid cell
population and as a median absolute cell number per microliter calculated from the total lymphocyte count (in parentheses)
Patient group Cell population
T CD3+ Th CD3+CD4+ Tc CD3+CD8+ B NK
TBE total (n = 9) 95 % (42) 79 % (30) 16 % (10) 0.4 % (<1) 3 % (3)
TBE—M (n = 6) 95 % (50) 81 % (43) 15 %a (8) 0.5 % (1) 4 % (3)
TBE—ME (n = 3) 96 % (42) 64 % (29) 28 %a (11) 0.3 % (<1) 2 % (1)
TBE tick-borne encephalitis, M meningitis, ME meningoencephalitis
ap < 0.05 for the difference between M and ME patients
Fig. 3 CCR5 expression in TBEV-infected patients compared to other
patient groups and healthy controls. Expression of CCR5 in the
activated Th lymphocyte population (CD3+CD4+CD45RO) measured
cytometrically as described in “Methods” and expressed as mean
fluorescence index (MFI). Comparison of values in peripheral blood (PB)
and cerebrospinal fluid (CSF) of patients with tick-borne encephalitis
(TBE), early cns neuroborreliosis (NB), and other aseptic meningitis (AM)
on admission to hospital (I), 10–14 days later (II) and 4–6 weeks later
(III), as well as in peripheral blood of subjects without meningitis/
encephalitis: with acute febrile infection without cns involvement (AF),
with headache of non-infectious etiology (H) (both groups—at
admission to hospital), and in healthy blood donors (C). Shown are
median (horizontal line), quadrilles (box), and minimum and maximum
values (whiskers); when only individual values are available in AM csf,
they are presented as circles; the empty circles to the left denote blood
samples from three patients studied in the peripheral phase of TBE, up
to 2 weeks between the onset of meningitis (not included in the
statistical analysis). There was no difference between the study groups
and examination time-points in the peripheral blood expression.
*significant difference between paired blood and csf examinations,
p < 0.05; **significant difference between paired blood and csf
examinations, p < 0.01; ***significant difference between paired blood
and csf examinations, p < 0.001; #significant difference between TBE
and NB csf, p < 0.05; &significant difference between the examination
on admission and during folow-up, p < 0.05
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meningoencephalitis groups (Fig. 4). CCR5 expression
did not differ between patients with mild and moder-
ate/severe TBE meningoencephalitis, between patients
with monophasic versus biphasic course of the dis-
ease, and patients with normal versus altered mental
status.
CCR5 csf expression on admission was significantly
(p < 0.05) higher in men than in women in TBE
group.
Genotyping
There were no CCR5Δ32 homozygotes identified in the
study groups. Five CCR5Δ32/wt heterozygotes were de-
tected among the healthy controls and 7 among geno-
typed TBE patients. Unfortunately, limited material was
available for cytometry from TBE CCR5Δ32/wt heterozy-
gotes, including paired blood and csf samples from 3 pa-
tients (in individual patients: from examinations I and II,
only examination I, only examination II) and only exam-
ination II–III blood samples from the remaining four.
The representative cytometric plots of CCR5 expres-
sion in CD3+CD4+ CD45RO cells in CCR5Δ32/wt het-
erozygote are shown in Fig. 5a. The CCR5 expression in
the peripheral blood was lower in CCR5Δ32 carriers
than in wt/wt homozygotes both in the terms of the
fraction of CCR5-positive cells and CCR5 MFI, but the
expression levels associated with both genotypes over-
lapped, especially in TBE patients in examinations II and
III (Fig. 5b). In csf samples from CCR5Δ32 heterozy-
gotes, CCR5 expression tended to be at the lower end of
values found in wt/wt genotype, but the enrichment in
CCR5+ cells was evident. Csf-activated Th population
contained from 17 to 41 % of CCR5-positive cells, over-
lapping with values from wt/wt heterozygotes (Fig. 5c).
Total lymphocytic pleocytosis was not reduced in
CCR5Δ32 bearers (Fig. 6), and the Th lymphocyte popu-
lation tended to be enriched in activated cells analo-
gously to the rest of TBE patients. The total protein and
albumin csf concentration did not differ between
CCR5Δ32/wt and wt/wt patients (not shown). Five of
CCR5Δ32/wt patients presented with meningoencephal-
itis of mild to moderate severity and only two with
meningitis, suggesting a tendency for a more severe
manifestation in the presence of CCR5Δ32, but the trend
was not statistically significant.
Chemokine expression
In the pilot analysis, serum concentrations of CCL3,
CCL4, and CCL5 did not differ between controls and pa-
tients with different forms of lymphocytic meningitis, in-
cluding TBE. Concentrations of CCL3 and CCL4 in csf
were not increased in any of the meningitis/encephalitis
groups in comparison with controls and were not higher
in csf than in serum, clearly not forming a chemotactic
gradient towards cns.
The csf concentration of CCL5 was significantly ele-
vated in TBE patients on admission and remained ele-
vated in examination II, although with a tendency to
decrease (Fig. 7a). The same tendency was present in the
groups of neuroborreliosis and the other aseptic menin-
gitis patients. In neuroborreliosis, the median CCL5 con-
centration tended to be threefold higher than in TBE,
although the difference did not reach the level of statis-
tical significance (Fig. 7b). CCL5 serum concentrations
in both TBE patients and controls were extremely high,
which is in accordance with the literature data and re-
flects a thrombocyte interference during the serum isola-
tion and handling and not the situation in vivo [46]. As
a result, CCL5 gradient between csf and serum could
not be evaluated.
Following that, csf CCL5 was studied in a larger group
of TBE patients, which confirmed its increased concentra-
tion and its decrease before discharge in comparison with
the examination on admission (p < 0.01) (Fig. 8). Median
CCL5 was significantly higher in patients with menin-
goencephalomyelitis in comparison with meningitis and
meningoencephalitis groups. In meningoencephalitis,
CCL5 concentration was not different in comparison with
Fig. 4 CCR5 expression in TBEV-infected patients dependent on the
clinical form of the disease. Expression of CCR5 in the activated Th
lymphocyte population (CD3+CD4+CD45RO) measured cytometrically
as described in “Methods” and expressed as mean fluorescence index
(MFI), in peripheral blood (PB) and cerebrospinal fluid (CSF) of patients
with the infection with tick-borne encephalitis virus (TBEV)
presenting as meningitis (M), meningoencephalitis (ME), and
meningoencephalomyelitis (MEM) as well as in peripheral blood
of patients with a mild flu-like TBEV infection (F) on admission
to hospital (I), 10–14 days later (II) and 4–6 weeks later (III).
Shown are median (horizontal line), quadrilles (box), and minimum and
maximum values (whiskers); in the least numerous groups, not allowing
for statistical analysis, only individual values are shown as circles instead.
There was no significant difference between the CCR5 expression in
patients with different clinical presentation of TBEV infection
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Fig. 5 CCR5 expression in a TBEV-infected patients with CCR5Δ32/wt versus wt/wt genotype. a FACS plots of peripheral blood (PBMC, upper panel) and
cerebrospinal fluid (csf, lower panel) obtained on admission to hospital from a TBE patient with CCR5Δ32/wt genotype. Left: T lymphocytes were gated based
on CD3 and side scatter dot plot (gate R1). Middle: CD4+CD45RO+ T lymphocytes were gated in selected R1 population based on CD4 and CD45RO dot
plot (gate R3). Isotype controls from the same blood and csf samples were used to define the CD45RO+ population. Gate R2 contains CD4+CD45-negative
T lymphocytes. Right: a histogram of CD195 expression intensity (dark gray) measured on gate R3 (light gray—isotype control). b CCR5 expression in the
activated Th lymphocytes population in the peripheral blood in TBEV-infected patients stratified by CCR5 genotype, measured as in A and expressed as MFI,
on admission (I), 10–14 days later (II) and 4–6 weeks later (III). Data from wt/wt homozygotes (n=20 in I, 25 in II, and 17 in III) and from CCR5Δ32/wt heterozygotes
(n = 3 at each time point) compared with healthy controls (C, n = 10 for wt/wt and 5 for CCR5Δ32/wt). Shown are median (horizontal line), quadrilles
(box), and minimum and maximum values (whiskers); in TBE CCR5Δ32/wt groups, individual values are shown as circles. *significant difference between
genotypes with p< 0.05; the same results were obtained when CCR5-positive cell fraction was analyzed instead of MFI as a measure of CCR5 expression;
c CCR5 expression (presented as MFI) in paired csf (CSF) and peripheral blood lymphocyte (PBL) populations from TBEV-infected patients on admission to
hospital; values from wt/wt homozygotes are shown as filled diamonds and from two CCR5Δ32/wt heterozygotes as empty symbols; the CCR5 expression
in CCR5Δ32/wt patients is low, but there is an apparent enrichment of the csf population in CCR5 expressing cells, analogously to wt/wt homozygotes
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the meningitis group and did not depend on the severity
of the cns involvement. It was significantly higher in pa-
tients with monophasic versus typical biphasic clinical
course of the disease. In a patient with a flu-like TBEV in-
fection, CCL5 in the csf was close to the lower end of
values found in TBE meningitis/meningoencephalitis
but still higher than in any of the control samples.
Finally, CCL5 csf concentration did not correlate with
CCR5 genotype.
Csf CCL5 concentration correlated significantly with
the total pleocytosis, lymphocyte count, total protein,
and albumin concentration. There was also a tendency
for a positive correlation with a number of CCR5-
positive activated Th cells per microliter, although it did
not reach the level of statistical significance (Fig. 9).
Discussion
Although an important role of CCR5 in flavivirus en-
cephalitis has been suggested by both animal models
and epidemiologic studies, to our knowledge, its expres-
sion has not been analyzed in a patient group with
respect to the clinical presentation and genetic back-
ground so far. To assess its role in TBE, we have studied
CCR5 in activated Th lymphocytes (CD3+CD4
+CD45RO+) in csf, a cell population that is relatively ac-
cessible, reflects the intrathecal inflammatory/immune
response, is important for TBEV clearance from cns, and
which appears to be preferentially recruited into csf of
TBE patients. Interestingly, in our pilot experiments, we
have found a tendency for a higher proportion of CD3
+CD8+ versus CD3+CD4+ lymphocytes in csf lymphoid
cell population in patients with the more severe mani-
festation of TBE, which is consistent with the hypothesis
that cytotoxic T cells are involved in TBE-related immu-
nopathology while Th cells we chose for the study are
protective [13, 18].
CCR5 is commonly expressed by intrathecal Th
lymphocytes in both infectious (neuroborreliosis) and
non-infectious (multiple sclerosis, MS) cns inflamma-
tion, usually alongside CXCR3 receptor for chemo-
kines CXCL9 and CXCL10, but its role remains
debatable [26, 28–30]. In MS, CXCR3 is considered
responsible for a lymphocyte migration, while the
presence of CCR5 is secondary to its expression on
the activated (CD45RO+) lymphocytes preferentially
recruited to the inflammatory csf [28, 29]. High
CCR5 expression has been observed on csf CD4+ and
CD8+ lymphocytes in neuroborreliosis, where it was
also co-expressed with CXCR3 [26, 27, 30]. According
to Giunti et al., CCR5 does not contribute signifi-
cantly to lymphocyte migration into csf in neurobor-
reliosis but may be up-regulated on activated Th
lymphocytes intrathecally and facilitate their subse-
quent migration to the nervous tissue [26]. In viral
encephalitis, the role of CXCR3 and CCR5 has been stud-
ied mainly in animal models and shows differences de-
pending on virus type and strain virulence [15, 20, 47].
The lack of CCR5 expression has no apparent conse-
quences in mice infected with lymphocytic choriomenin-
gitis virus [23] and paradoxically increases leukocyte
influx and intrathecal inflammation in murine model of
herpes simplex type 1 encephalitis [48]. On the other
hand, CCR5 seems to be functional and active alongside
Fig. 6 The cerebrospinal fluid cytosis in TBEV-infected patients
stratified by CCR5 genotype. The total pleocytosis (P) and csf
lymphocyte count (L) on admission to hospital in TBEV-infected
patients with wt/wt (n = 39) and CCR5Δ32/wt (n = 7) genotype (data
from a single wt/wt patient with an extremely high initial pleocytosis
of 1196 cells/μl are not shown for clarity). Shown are median
(horizontal line), quadrilles (box), and minimum and maximum values
(whiskers). There was no significant difference between the patients
with different genotypes
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Fig. 7 Concentrations of CCR5 ligands in cerebrospinal fluid of TBEV-infected patients. Concentrations of CCL3, CCL4, and CCL5 in the cerebrospinal
fluid of a pilot group of TBE patients on admission to hospital (I, n = 11) and in the early convalescent period after 10–14 days (II, n = 6) measured
immunoenzymatically as described in “Methods” and expressed in pg/ml. The detection limit was 10 pg/ml for CCL3, 4 pg/ml for CCL4, and 2 pg/ml
for CCL5. Shown are median (horizontal line), quadrilles (box), and minimum and maximum values (whiskers). a Elevated concentration of CCL5, but not
CCL3 and CCL4, in comparison with controls with no infectious nor inflammatory pathology (C, n = 5); *significant difference in comparison with C
(p << 0.05); **significant difference in comparison with C, p < 0.01; b Concentration of CCL5 in TBE on admission compared to neuroborreliosis (NB,
n = 4) and aseptic meningitis (AM, n= 4) patients—no statistically significant difference between the groups, *significantly higher median concentration in
comparison with controls
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CXCR3 in WNV-encephalitis model [19, 32]. CCR5-
negative knock-out mice have a normal inflammatory/im-
mune response in the periphery, but leukocyte migration
into cns is impaired, accompanied by an inability to clear
virus from the brain tissue and an increased mortality.
The expression of other chemokine receptors (CCR1,
CCR2, CXCR3) and of chemokines (CXCL9, CXCL10,
CCL2, CCL3, CCL4, and CCL5) is increased but is unable
to compensate for the lack of CCR5, suggesting that
the CCR5 role in the infection with neurotropic flavi-
virus is non-redundant and distinct from encephaliti-
des of other etiology [32]. However, CXCR3 has been
found on csf Th lymphocytes from TBE patients, and
its ligand CXCL10 has been detected simultaneously
in csf by Lepej et al., so the contribution from this
receptor remains probable too [16].
In our group of TBEV-infected patients, an activated
Th lymphocyte population in csf was enriched in CCR5-
expressing cells, suggesting that either they were prefer-
entially attracted into csf or that, alternatively, CCR5
was up-regulated on activated Th lymphocytes in the
pro-inflammatory csf environment, possibly influencing
their further trafficking, as suggested by Giunti et al. for
neuroborreliosis [26]. Both possibilities are not mutually
exclusive and point to CCR5 involvement in TBE patho-
genesis. Because of a suspected particular role of CCR5
in flavivirus infections, we expected its expression to be
higher in TBE compared to other forms of meningitis.
Fig. 8 Variability of CCL5 concentration in cerebrospinal fluid of TBEV-infected patients. Elevated concentration of CCL5 in the cerebrospinal fluid of a
group of TBE patients on admission to hospital (I, n= 56) and in the early convalescent period after 10–14 days (II, n= 47) measured immunoenzymatically
as described in “Methods,” in picograms per milliliter (pg/ml). Lower detection limit was 2 pg/ml. Shown median (horizontal line), quadrilles (box), and
extreme values (whiskers). a Patients stratified dependent on the clinical manifestation of TBEV infection: meningitis (M, n= 22), meningoencephalitis (ME,
n= 29), meningoencephalomyelitis (MEM, n= 4); *significantly higher in MEM comparison with the two other groups (p< 0.05); a value in a single patient
with a flu-like infection is shown to the right as an empty circle; b Patients with meningoencephalitis stratified dependent on the clinical severity: mild
(n= 12), moderate to severe (with paresis, multifocal neurologic signs, and/or altered consciousness; n= 17); c Patients with meningoencephalitis stratified
dependent on the mental status: normal (n= 14), abnormal (agitation, disorientation, somnolence, n= 15); d Comparison between the groups of patients
with the monophasic (n= 27) versus biphasic (n= 27) clinical course of the disease, *significant difference with p< 0.05; e Subgroup of 42 patients with
TBEV infection stratified by the CCR5 genotype: wt/wt (n= 32) or CCR5Δ32/wt (n= 10)
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This was, however, not the case as the CCR5 csf expres-
sion was higher in neuroborreliosis than in TBE. The
feature specific for TBE was a tendency for a continuing
increase of CCR5 expression at least between the time of
hospital admission and early convalescent period 2 weeks
later, contrasting with the decrease in other patient
groups. These trends are consistent with a relatively low
initial lymphocyte count accompanied by the prolonged
inflammatory changes in TBE csf, described in previous
studies and observable in our study group as well [49].
Vividly increased expression of CCL5 in brains of mice
with WNV-encephalitis and TBE suggests it as a main
CCR5 ligand in this setting [32, 50, 51]. Our previous re-
sults pointed to a possible role of two of CCR5 ligands,
CCL5 (RANTES) and CCL3 (MIP-1α) in TBE pathogen-
esis, although their chemotactic gradient towards csf
could not be proven [52, 53]. In the recent study, Palus
et al. found no increased CCL3, CCL4, and CCL5 con-
centrations in serum of TBE patients, which is in agree-
ment with our current results [54]. On the other hand,
we have confirmed the concentration of CCL5, but not
CCL3 and CCL4, to be significantly increased in the csf
of the pilot group of TBE patients. When subsequently
studied in a larger patient group, CCL5 csf concentra-
tion was increased in comparison with healthy controls,
correlated with the csf inflammatory parameters and
tended to correlate with the csf Th CCR5 expression.
When we compared CCL5 expression between TBE,
neuroborreliosis, and other aseptic meningitis patients,
the differences between these groups were analogous to
the trends observed for CCR5 expression: in TBE, the
initial CCL5 concentration was low in comparison with
Fig. 9 Correlation of the CCL5 concentration with cerebrospinal fluid cytometric parameters. Correlation of the CCL5 concentration in the
cerebrospinal fluid (horizontal axis, pg/ml) with csf cytometric parameters (vertical axis, cell/μl) in TBEV-infected patients, measured and calculated
as described in “Methods”; a Csf lymphocyte count—significant correlation with a strength of 0.38 and p < 0.05; b The absolute number of CCR5-
positive activated Th lymphocytes (T CD3+CD4+CD45RO CCR5+ cells)—an analogous tendency for a positive correlation as in A, not reaching
the level of statistical significance. NS not significant
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neuroborreliosis, but its increase was characteristically
protracted into the convalescent phase. These data are
consistent with CCL5 and CCR5 cooperating in driving
lymphocyte migration into csf in TBE and influencing
the course of the intrathecal inflammation. CCL5 con-
centration was relatively high in TBE patients with
meningoencephalomyelitis, who also had a tendency for
a higher intrathecal CCR5 expression and pleocytosis.
The other studies also show the correlation of the intra-
thecal concentrations of CCR5 ligands with a severity of
neurologic involvement. The mouse strains genetically
susceptible to TBEV present with a higher expression of
CCL3, CCL4, and CCL5 in the brain parenchyma during
experimental TBE compared to relatively resistant
strains [55], and high CCL5 concentration in patients in-
fected with Japanese encephalitis virus is associated with
mortality [56]. Interestingly, in a patient with a flu-like
TBEV infection, a concentration of CCL5 in csf was
higher than in any of the healthy controls, without any
signs of concomitant or subsequent intrathecal inflam-
mation, suggesting CCL5 intrathecal up-regulation even
without the clinically overt cns infection.
Another line of evidence supporting the role of CCR5
in flavivirus infection comes from the studies comparing
CCR5 genotypes in patients with healthy subjects. Ac-
cording to Glass et al. and Lim et al., CCR5Δ32 homozy-
gotes have a several-fold increased risk of a symptomatic
WNV infection [37, 38]. The data suggest that almost all
infected CCR5Δ32 homozygotes develop a symptomatic
disease versus a minority of the general population [19].
The increased frequency of CCR5Δ32 allele and
CCR5Δ32/CCR5Δ32 genotype has been detected in
Lithuanian patients with TBE [41, 42], but not in pa-
tients from Novosibirsk area (Asiatic part of Russia)
likely infected with the Siberian TBEV subtype [7, 57].
The discrepancy between the European and Siberian
TBE studies could result from the influence of genetic
background in distinct human populations or from the
differences between two separate TBEV types. The main
difference between the results of WNV and European
TBEV studies was the susceptibility of CCR5Δ32/wt het-
erozygotes. No association of CCR5Δ32 heterozogosity
with WNV infection was observed, suggesting that even
a reduced expression of CCR5 is sufficient for protection
[39], but in the European patients, increased TBE risk
was associated with CCR5Δ32 heterozogosity, as if the
quantitatively changed CCR5 expression was sufficient
to alter susceptibility to TBEV [41]. The reasons for that
difference are unclear, especially that mechanisms by
which CCR5 deficiency could influence susceptibility to
flavivirus in humans has not been studied. The simple
explanation in agreement with the animal models is an
impaired lymphocyte influx into cns, resulting in a more
significant and clinically manifest neuroinfection [39].
However, this would also favor clinically more severe cns
involvement, which has not been confirmed [38, 39, 42].
In the contrary, a large epidemiologic study of blood do-
nors has shown that the CCR5Δ32 correlates with the risk
of any clinically overt WNV-related disease (including
mild flu-like infections) versus asymptomatic infection
and not specifically with meningitis/encephalitis [40]. That
suggests that CCR5Δ32 associates with the impairment of
the early peripheral response to WNV and TBEV resulting
in the occurrence of the symptomatic disease, while its
connection with neuroinvasion and intrathecal response
in unclear.
Consistent with the previous studies, we have not ob-
served an evident difference in the clinical presentation
between TBE patients with CCR5Δ32/wt and wt/wt
genotype neither in the group presented here nor in a
larger population of genotyped patients from our center
(unpublished data). There was also no difference in csf
inflammatory parameters between CCR5Δ32/wt and wt/
wt TBE patients. That suggests that either (1) CCR5
does not play a role in driving lymphocyte migration
into cns in TBE, (2) CCR5 drives lymphocyte migration
in TBE but its impaired expression may be compensated
by alternative pathways, or (3) CCR5 drives lymphocyte
migration in TBE, but its expression in CCR5Δ32/wt is
induced to a level sufficient to fulfill that role. We
attempted to clarify this by comparing a phenotypic
CCR5 expression in TBE patients with both genotypes.
As expected, the peripheral Th lymphocyte CCR5 ex-
pression in CCR5Δ32/wt heterozygotes was lower than
in wt/wt homozygotes both in healthy controls and in
TBE patients on admission to hospital, but in TBE, the
difference became insignificant in the early convalescent
period. This may be an artifact due to a small number of
CCR5Δ32/wt samples, but if confirmed in a larger group
of patients, it could also suggest a compensatory CCR5
up-regulation in response to TBEV challenge. More im-
portantly, the CCR5 expression in csf obtained from
three CCR5Δ32/wt TBE patients was several-fold in-
creased in comparison with blood and reached the lower
end of a value range found in wt/wt homozygotes. This
suggest that the expression of CCR5 and/or its ligands
was up-regulated to a level sufficient for a Th lympho-
cyte migration to cns and effective virus control, consist-
ent with a normal pleocytosis and an unremarkable
clinical presentation in CCR5Δ32/wt patients. CCL5
level in csf was not increased in CCR5Δ32/wt versus wt/
wt genotype, so it seems not directly involved in a
compensation for an impaired CCR5 expression. As
CCR5Δ32/wt patients seem to have a normal intrathecal
response to TBE, the increased susceptibility to TBEV
associated with this genotype should depend on the im-
pairment of the early, peripheral response, during the
first febrile phase or even locally at the tick-bite site,
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which agrees with the conclusions from epidemiologic
observations by Lim et al., who have suggested a similar
mechanism for an increased susceptibility to WNV in
CCR5Δ32/CCR5Δ32 homozygotes [40].
CCR5Δ32 variant is present in a small minority of TBE
patients, including 2.3 % of CCR5Δ32 homozygotes in
the Lithuanian TBE group [41] and only 7 CCR5Δ32/wt
heterozygotes in our study, so additional predisposing
factors must be involved in the remaining cases. As evi-
dent in our results as well, the expression of CCR5 in
peripheral blood T lymphocytes in CCR5 wt/wt homozy-
gotes is highly variable. Several common genetic poly-
morphisms associated with that variability have been
identified in the promoter region of CCR5 and in the
genes for CCR5 ligands, CCL5 and CCL3L1, the latter
probably influencing CCR5 expression indirectly,
through their association with the CCL3 and CCL5 syn-
thesis [44, 58, 59]. We have hypothesized that the vari-
ability of CCR5 expression associated with factors other
than CCR5Δ32 allele should have a similar clinical effect
and contribute to a variable response to TBEV in the
CCR5 wt/wt population. To verify that we have studied
CCR5 in the peripheral blood Th cells in patients 6–
8 weeks after the hospital admission for TBE, after the
normalization of the clinical signs and symptoms and
the inflammatory parameters in the periphery, we con-
sider it a proxy of the constitutive baseline level. In fact,
as we detected no hint of any dynamics of the peripheral
CCR5 expression in CCR5 wt/wt homozygotes in the
course of TBE, the values measured in the neurologic
phase could be considered close to the baseline too.
However, the median expression at any of the time
points studied did not differ from the results in healthy
controls and in other patient groups, which is especially
striking in the face of a high individual variability. It
could be speculated that TBE patients had originally
lower CCR5 peripheral expression than controls, masked
by a prolonged up-regulation lasting from the onset of
meningitis/encephalitis to the late convalescent period.
This assumption could be definitely dismissed only by a
systematic study of patients with a history of TBE at still
later time points, months to years after infection, to
check if there is any sign of the return to a hypothetical
lower baseline level. Alternatively, a study of CCR5 ex-
pression patients in a first phase of TBE before the onset
of meningitis and the ones with a mild flu-like TBEV in-
fection would be informative as for its role in the early
response but is difficult to conceive as these patients are
rarely diagnosed and hospitalized. Our observations with
that respect are fragmentary: in three patients in whom
peripheral blood lymphocyte CCR5 was measured in the
first phase of the infection and who later developed
meningitis, it was within the range of values found in
other groups, as it was in three patients with a mild flu-
like infection without cns involvement, not giving evi-
dence for any inter-group variability or dynamical
change of CCR5 expression before the cns invasion. At
present, there is no data to support the association be-
tween the low constitutive CCR5 expression in the per-
ipheral blood-activated Th cells and the susceptibility to
TBEV in persons with a CCR5 wt/wt genotype.
Conclusions
Our results support the pathogenetic role of CCR5 and its
ligand CCL5 in the neurologic phase of TBEV infection.
The expression of CCR5 in activated Th lymphocytes was
not particularly high in TBE patients comparing with
other viral and borrelial meningitis but was relatively
long-lasting and correlated with other parameters of the
intrathecal inflammation. Our study did not address the
role of other chemokine receptors, which may be co-
expressed and cooperate with CCR5. The possible co-
expression of CCR5 and CXCR3 in the Th cell population
and their relative importance for the lymphocyte migra-
tion warrants a further study, which could further clarify
the role of CCR5 in this setting as well.
We did not detect evidently impaired CCR5 expres-
sion or any features of altered intrathecal inflammatory
response in TBE patients heterozygous for CCR5Δ32 al-
lele, and we infer that the CCR5 expression is induced
to a level adequate for the effective lymphocyte migra-
tion to cns in them. The observed increased incidence of
TBE in CCR5Δ32 bearers may depend on the impaired
early peripheral response to TBEV, possibly even at the
tick-bite site before the further virus spread, which re-
quires further study. However, we found no evidence
that, besides a relatively rare CCR5Δ32 variant, a low
baseline expression of CCR5 in the peripheral blood
lymphocytes may be a marker of an increased suscepti-
bility to flavivirus.
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